Currently, studies have shown that TFs might be as new therapy target for cancer in clinical settings by modulating their expression or degradation, blocking protein/protein interactions, or targeting the TF itself to prevent its DNA binding either through a binding pocket or at the DNA-interacting site (4, 24, 25). This evidence concerns the gene TF and cancer.